176 related articles for article (PubMed ID: 26370619)
1. Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stages II/III colon cancer.
Sebio A; Matsusaka S; Zhang W; Yang D; Ning Y; Stremitzer S; Stintzing S; Sunakawa Y; Yamauchi S; Fujimoto Y; Ueno M; Lenz HJ
Pharmacogenomics J; 2016 Aug; 16(4):312-9. PubMed ID: 26370619
[TBL] [Abstract][Full Text] [Related]
2. A functional germline variant in GLI1 implicates hedgehog signaling in clinical outcome of stage II and III colon carcinoma patients.
Szkandera J; Pichler M; Absenger G; Stotz M; Weissmueller M; Samonigg H; Asslaber M; Lax S; Leitner G; Winder T; Renner W; Gerger A
Clin Cancer Res; 2014 Mar; 20(6):1687-97. PubMed ID: 24470513
[TBL] [Abstract][Full Text] [Related]
3. Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.
Bohanes P; Yang D; Loupakis F; LaBonte MJ; Gerger A; Ning Y; Lenz C; Lenz F; Wakatsuki T; Zhang W; Benhaim L; El-Khoueiry A; El-Khoueiry R; Lenz HJ
Pharmacogenomics J; 2015 Jun; 15(3):226-34. PubMed ID: 25487679
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant chemotherapy increase survival and decrease recurrence in stage IIA colon cancer.
Yun HR; Kim HC; Yun SH; Lee WY
Hepatogastroenterology; 2012; 59(120):2466-71. PubMed ID: 23169179
[TBL] [Abstract][Full Text] [Related]
5. Genetic variants within obesity-related genes are associated with tumor recurrence in patients with stages II/III colon cancer.
Sebio A; Gerger A; Matsusaka S; Yang D; Zhang W; Stremitzer S; Stintzing S; Sunakawa Y; Yamauchi S; Ning Y; Fujimoto Y; Ueno M; Lenz HJ
Pharmacogenet Genomics; 2015 Jan; 25(1):30-7. PubMed ID: 25379721
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of oral tegafur-uracil as maintenance therapy following intravenous 5-fluorouracil chemotherapy in stage III colon cancer.
Hong KD; Lee SI; Moon HY
Hepatogastroenterology; 2012; 59(113):104-7. PubMed ID: 22251527
[TBL] [Abstract][Full Text] [Related]
7. Ubiquitin D is an independent prognostic marker for survival in stage IIB-IIC colon cancer patients treated with 5-fluoruracil-based adjuvant chemotherapy.
Zhao S; Jiang T; Tang H; Cui F; Liu C; Guo F; Lu H; Xue Y; Jiang W; Peng Z; Yan D
J Gastroenterol Hepatol; 2015 Apr; 30(4):680-8. PubMed ID: 25238407
[TBL] [Abstract][Full Text] [Related]
8. Cancer Stem Cell Gene Variants in CD44 Predict Outcome in Stage II and Stage III Colon Cancer Patients.
Stotz M; Herzog SA; Pichler M; Smolle M; Riedl J; Rossmann C; Bezan A; Stöger H; Renner W; Berghold A; Gerger A
Anticancer Res; 2017 Apr; 37(4):2011-2018. PubMed ID: 28373475
[TBL] [Abstract][Full Text] [Related]
9. TS gene polymorphisms are not good markers of response to 5-FU therapy in stage III colon cancer patients.
Fariña-Sarasqueta A; Gosens MJ; Moerland E; van Lijnschoten I; Lemmens VE; Slooter GD; Rutten HJ; van den Brule AJ
Cell Oncol (Dordr); 2011 Aug; 34(4):327-35. PubMed ID: 21630057
[TBL] [Abstract][Full Text] [Related]
10. Colon cancer cells escape 5FU chemotherapy-induced cell death by entering stemness and quiescence associated with the c-Yes/YAP axis.
Touil Y; Igoudjil W; Corvaisier M; Dessein AF; Vandomme J; Monté D; Stechly L; Skrypek N; Langlois C; Grard G; Millet G; Leteurtre E; Dumont P; Truant S; Pruvot FR; Hebbar M; Fan F; Ellis LM; Formstecher P; Van Seuningen I; Gespach C; Polakowska R; Huet G
Clin Cancer Res; 2014 Feb; 20(4):837-46. PubMed ID: 24323901
[TBL] [Abstract][Full Text] [Related]
11. Effect of HtrA1 Polymorphism on Sensitivity to Chemotherapy in Patients with Colon Cancer.
Yao Y; Li N
Med Sci Monit; 2020 Mar; 26():e921933. PubMed ID: 32218415
[TBL] [Abstract][Full Text] [Related]
12. Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival.
Yuan H; Liu H; Liu Z; Zhu D; Amos CI; Fang S; Lee JE; Wei Q
Int J Cancer; 2015 Aug; 137(3):638-45. PubMed ID: 25628125
[TBL] [Abstract][Full Text] [Related]
13. Toxicity and effects of adjuvant therapy in colon cancer: results of the German prospective, controlled randomized multicenter trial FOGT-1.
Staib L; Link KH; Beger HG;
J Gastrointest Surg; 2001; 5(3):275-81. PubMed ID: 11419451
[TBL] [Abstract][Full Text] [Related]
14. LGR5 rs17109924 is a predictive genetic biomarker for time to recurrence in patients with colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy.
Szkandera J; Herzog S; Pichler M; Stiegelbauer V; Stotz M; Schaberl-Moser R; Samonigg H; Asslaber M; Lax S; Leitner G; Renner W; Lenz HJ; Berghold A; Gerger A
Pharmacogenomics J; 2015 Oct; 15(5):391-6. PubMed ID: 25665511
[TBL] [Abstract][Full Text] [Related]
15. Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.
Ning Y; Gerger A; Zhang W; Hanna DL; Yang D; Winder T; Wakatsuki T; Labonte MJ; Stintzing S; Volz N; Sunakawa Y; Stremitzer S; El-Khoueiry R; Lenz HJ
Mol Cancer Ther; 2014 Feb; 13(2):528-39. PubMed ID: 24170770
[TBL] [Abstract][Full Text] [Related]
16. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
[TBL] [Abstract][Full Text] [Related]
17. Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.
Páez D; Gerger A; Zhang W; Yang D; Labonte MJ; Benhanim L; Kahn M; Lenz F; Lenz C; Ning Y; Wakatsuki T; Loupakis F; Lenz HJ
Pharmacogenomics J; 2014 Apr; 14(2):142-50. PubMed ID: 23817222
[TBL] [Abstract][Full Text] [Related]
18. Genetic variability of genes in NER pathway influences the treatment outcome of gastric cancer.
Xue MH; Li GY; Wu XJ; Zhang CX; Zhang CF; Zhu KX
Int J Clin Exp Pathol; 2015; 8(5):5563-9. PubMed ID: 26191265
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Peritoneal Recurrence in Stage II to III Colon Cancer.
Mayanagi S; Kashiwabara K; Honda M; Oba K; Aoyama T; Kanda M; Maeda H; Hamada C; Sadahiro S; Sakamoto J; Saji S; Yoshikawa T
Dis Colon Rectum; 2018 Jul; 61(7):803-808. PubMed ID: 29561282
[TBL] [Abstract][Full Text] [Related]
20. Value of gene polymorphisms as markers of 5-FU therapy response in stage III colon carcinoma: a pilot study.
Fariña-Sarasqueta A; van Lijnschoten G; Rutten HJ; van den Brule AJ
Cancer Chemother Pharmacol; 2010 Nov; 66(6):1167-71. PubMed ID: 20665215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
